CoChat

Benzodiazepines Revisited

Open access
Balon, Richard · 2013 · Psychotherapy and Psychosomatics
Cited by 45

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Since the arrival of chlordiazepoxide in 1959 and diazepam in 1960, benzodiazepines (BZPs) have been hesitantly lauded and frequently enthusiastically vilified by many. Nevertheless, new BZPs have been synthesized and by now, there are almost forty of them available around the world. This number alone is certainly a testimony to their wide use, usefulness and efficacy. Their anxiolytic properties are unquestionable. BZPs have been used in numerous clinical conditions and diagnoses - from all anxiety disorders (as defined by whatever diagnostic system) to sleep disorders, alcohol withdrawal and the augmentation of antidepressants and antipsychotics as well as for mania, muscle relaxation, seizures and in many other approved and nonapproved indications.Interestingly, psychiatrists have been, at least in my experience, hesitant to use BZPs. This hesitancy has been reinforced by the emphasis on possible dependence, toxicity and abuse. Yet these issues have been overstated and overemphasized. In 1990, the American Psychiatric Association published a small monograph compiled by the American Psychiatric Association Task Force on Benzodiazepine Dependency, led by Carl Salzman [1]. The report focused specifically on the development of physiological dependence, especially at therapeutic doses, on acute and chronic toxicity and on the possible recreational use of BZPs as well as looking at the patterns of prescription and clinical use and on enabling psychiatrists to ‘weight the relative benefits versus the risk of using benzodiazepines' and to develop some guidelines for the appropriate use of BZPs in clinical practice. The conclusion (too long to be cited in its entirety) contains a lot of interesting information. At that time, there were no data ‘to suggest that long-term therapeutic use of benzodiazepines by patients commonly leads to dose escalation or to recreational abuse' [[1], p. 55] (in all fairness, this was before the introduction of short half-life BZPs). The text stated that, at those times, a certain small percentage of patients used therapeutic doses of BZPs for self-medication of symptoms. The conclusion also discussed the development of physiological dependence, discontinuance symptoms and the relationship of the timing and severity of these to the half-life of the drug and the side effects of BZPs. The authors concluded that automobile driving is neither predictably nor consistently impaired by repeated therapeutic BZP doses. The report also noted that BZPs do not strongly reinforce their own use and are not widely abused drugs and that when abuse does occur, it is almost always among individuals who are also actively abusing alcohol, opiates or other sedative hypnotics [[1], p. 58]. The Task Force, after much cautious discussion and deliberation, came out in favor of careful prescribing of BZPs. The experts suggested that the benefits of BZPs clearly outweigh their hazards ‘(1) in patients with demonstrable persistent anxiety or dysphoric disorder or anxiety as a component of medical illness that cannot be otherwise treated and (2) in patients with chronic panic or agoraphobic disorder when benzodiazepines are deemed the preferred pharmacological drug by the clinician' [[1], p. 60].Reviewing this carefully crafted report, the reader gets the message - BZPs are efficacious and clinically useful, yet they have some problems and should be prescribed judiciously. Well, this statement would probably fit any class of psychotropic medications. Nevertheless, BZPs are perceived as problematic for patients suffering from anxiety disorders such as panic or agoraphobia, and medications such as selective serotonin reuptake inhibitors (SSRIs) are promoted as being safer and more efficacious (although in some studies, the perceived lesser efficacy may just be the matter of the underdosing of BZPs). Now, Offidani et al. [2] and before them Berney et al. [3] present us with the sad message that the change in prescribing pattern favoring newer antidepressants over BZPs in the treatment of anxiety occurred without supporting evidence! Offidani et al. [2] also write that in trials comparing BZPs with newer antidepressants, BZPs were more efficacious and had fewer adverse effects in patients suffering from generalized anxiety disorder or panic disorder.One wonders why the shift of opinion and the shift in the use of BZPs happened in this era of evidence-based medicine, without proper evidence? The explanation, in my opinion, is probably mainly due to the masterful propaganda of the pharmaceutical industry. At the time of the introduction of SSRIs and other new antidepressants, very little was known about their side effects. This usually happens with new classes of medications, as the long-term effects are detected only with long-term use, while the studies needed for regulatory approval are short-term. Would anyone believe that the frequency of sexual side effects associated with fluoxetine is just 1.8% as was noted at

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000353599

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 1

  1. 10.1001%2Fjama.299.9.1063 · DOI

Cited by

Metadata

Authors
Balon, R.
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2013
Volume
82
Issue
6
Pages
353-354
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W4233247469
Cited by
45
References
1
FWCI
0.90
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.